Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 304
- Registration Number
- NCT06478550
- Locations
- 🇬🇷
University Hospital of Athens ATTIKON, Haidari-Athens, Attica, Greece
🇬🇷General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Nea Efkarpia, Greece
🇬🇷"Laiko" General Hospital of Athens, Goudi/Athens, Greece
A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 120
- Registration Number
- NCT06478563
- Locations
- 🇺🇸
Celerion, Lincoln, Lincoln, Nebraska, United States
A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT06461039
- Locations
- 🇨🇦
Altasciences Clinical Company, Inc, Montreal, Quebec, Canada
A Research Study of the Effect of Food on Etavopivat in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT06433661
- Locations
- 🇺🇸
ICON-Salt Lake City, Salt Lake City, Utah, United States
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 240
- Registration Number
- NCT06409130
- Locations
- 🇧🇬
UMHAT "Sv. Ivan Rilski", Clinic of Gastroenterology, Sofia, Bulgaria
🇧🇬UMHAT Aleksandrovska, Sofia, Bulgaria
🇧🇬"DCC XX - Sofia" EOOD, Sofia, Bulgaria
Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 150
- Registration Number
- NCT06403761
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 300
- Registration Number
- NCT06388187
- Locations
- 🇺🇸
Aurora FDRC Inc., Costa Mesa, California, United States
🇺🇸Clinical Trial Res Assoc,Inc, Plantation, Florida, United States
🇺🇸Midwest Inst For Clin Res, Indianapolis, Indiana, United States
A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT06370819
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34238
- Registration Number
- NCT06351748
- Locations
- 🇨🇳
Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin, China
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 404
- Registration Number
- NCT06340854
- Locations
- 🇺🇸
Advanced Investigative Medicine, Inc., Hawthorne, California, United States
🇺🇸Scripps Whittier Diabetes Inst, La Jolla, California, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States